[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649825":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with RRMM",null,"RRMM patients being treated with SOC commercial BCMA CAR-T therapy",[13],"Other: Standardized neurocognitive testing",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Standardized neurocognitive testing","Perform standardized neurocognitive testing at baseline and serially at 1-, 6-, and 12-months post-infusion.",[9],[20],{"name":21,"affiliation":22,"role":23},"Cindy Varga, MD","Atrium Health Levine Cancer","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Courtney Schepel","CONTACT","980-292-0817","courtney.schepel@advocatehealth.org",[31],{"facility":22,"status":10,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Charlotte","North Carolina","28204","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-80.84313,35.22709,{"lat":41,"lon":40},[44,45],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":6},"Atrium Health Wake Forest Baptist","100649825","neurocognitive-trajectories-after-bcma-car-t-100649825",false,"NCT07740317","Neurocognitive Trajectories After BCMA CAR-T","Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma","CAR-T Cog","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign an IRB-approved informed consent\n2. Ability to retain independent decision-making capacity as per the enrolling investigator\n3. Age ≥ 18 years of age at the time of consent\n4. Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician\n5. Ability to read and understand the English language\n6. ECOG 0-2\n7. If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician\n8. Reliable access to internet access; a tablet, laptop and\u002For desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report\n9. Ability to complete required assessments, as determined by the treating clinician\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) disease\n2. Known neurodegenerative disease or major neurocognitive disorder\n3. Stroke and\u002For traumatic brain injury (TBI) within 12 months\n4. Concurrent investigational neuroactive drugs","ALL","18 Years",{"count":62,"type":63},50,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).",[67,68,69],"Multiple Myeloma (MM)","CART Therapy","Refractory Multiple Myeloma (RRMM)",[71],"cancer","NOT_YET_RECRUITING","2026-07-28",{"date":75,"type":76},"2026-07-31","ACTUAL",{"date":78,"type":63},"2026-09",{"date":80,"type":63},"2029-11",{"name":5,"class":6},1]